Revised forecast
Fiscal year ending September 2026 · Full yearPrevious forecast published 11 March 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Recognition of ¥100 million in revenue as an upfront contract fee upon entering into an agreement with Maruishi Pharmaceutical Co., Ltd., and a decrease of approximately ¥108 million in current-year expenses due to the timing of expenditures for the development of a commercial formulation for vocal fold scarring and related costs shifting to the next fiscal year.
| Item | Details |
|---|---|
| Net Sales | ¥332 million → ¥442 million（+33.1%） |
| Operating profit | ¥-1,018 million → ¥-800 million |
| Ordinary income | ¥-1,018 million → ¥-796 million |
| Profit attributable to owners of the parent | ¥-1,020 million → ¥-799 million |
| Net income per share | -139.85 yen and sen → -103.52 yen and sen |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 11 March 2026 |
| Previous-period results | Fiscal year ended September 2025: Revenue: ¥72 million; operating loss: ¥909 million; ordinary loss: ¥914 million; net loss: ¥916 million; net loss per share: ¥133.92 |
| Reason for the revision | Recognition of ¥100 million in revenue as an upfront contract fee upon entering into an agreement with Maruishi Pharmaceutical Co., Ltd., and a decrease of approximately ¥108 million in current-year expenses due to the timing of expenditures for the development of a commercial formulation for vocal fold scarring and related costs shifting to the next fiscal year. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue is expected to increase because a ¥100 million upfront contract fee will be recognized as revenue upon entering into an exclusive sales license agreement and related agreements with Maruishi Pharmaceutical Co., Ltd. In addition, the timing of expenditures for the development of a commercial formulation for vocal fold scarring and related costs has shifted to the next fiscal year, and current-year expenses are now expected to decrease by approximately ¥108 million.